A Phase 2 interventional study of Nemolizumab and Placebo in Atopic Dermatitis, sponsored by Galderma R&D. Completed at 67 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-22.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
17 studies in Dermatitis, Atopic by Galderma Group AG: 3 open now, 3 under way, 1 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 2, and was the 4th registered.
Galderma Group AG’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
Among Galderma Group AG’s 17 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
The aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving topical corticosteroids, who were not adequately controlled with topical treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects must fulfill one of the criteria below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nemolizumab (low dose)
Drug: Nemolizumab
Nemolizumab (medium dose)
Drug: Nemolizumab
Nemolizumab (high dose)
Drug: Nemolizumab
Nemolizumab placebo
Drug: Placebo
Injection every 4 weeks during 24 weeks (last injection at week 20)
Injection every 4 weeks during 24 weeks (last injection at week 20)
Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
Time frame: From Baseline to Week 24
Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24
The 4-point pruritus categorical scale was provided in their local language for the participants to report the intensity of their pruritus. Overall itching was scored as 0 for absence of pruritus and 3 for severe pruritus (bothersome itching/scratching that disturbs sleep). Higher scores indicate worse outcome.
Time frame: Week 24
Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
Time frame: From Week 1 to Week 24
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24
SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.
Time frame: Baseline, Week 24
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24
SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.
Time frame: Baseline, Week 24
Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.
Time frame: Baseline, Week 24
Number of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24
IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.
Time frame: From Week 1 to Week 24
Number of Participants With Eczema Area and Severity Index (EASI)-50 (Defined as Achieving 50% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
EASI is a composite score ranging from 0 to 72. The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
Time frame: From Week 1 to Week 24
Number of Participants With Eczema Area and Severity Index (EASI)-75 (Defined as Achieving 75% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
Time frame: From Week 1 to Week 24
Number of Participants With Eczema Area and Severity Index (EASI)-90 (Defined as Achieving 90% Reduction From Baseline in EASI Score) at Each Visit up to Week 24
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
Time frame: From Week 1 to Week 24
Number of Participants Achieving Investigator Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) and a Reduction of ≥2 Points at Each Visit up to Week 24
IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.
Time frame: Week 1 to Week 24
Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Each Visit up to Week 24
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
Time frame: From Baseline to Week 24
Percentage Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
Time frame: At baseline and Week 24
Number of Participants With Adverse Events
To evaluate the safety of nemolizumab in participants with moderate-to-severe AD
Time frame: From screening to Follow-up visit (Week 32)/Early termination visit
Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
Time frame: Baseline to Week 24
Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
Time frame: Baseline to Week 24
Percentage Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
Time frame: Baseline to Week 24
This study was conducted at 57 investigational sites in Australia, Canada, Germany, France, Poland and the United States.
| Milestone | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Started | 57 | 55 | 57 | 57 |
| Completed | 43 | 44 | 50 | 45 |
| Not completed | 14 | 11 | 7 | 12 |
| Withdrew: Adverse event | 0 | 3 | 2 | 3 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 7 | 4 | 8 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
| percentage change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | -58.4 ± 31.99 | -72.2 ± 25.96 | -73.4 ± 29.67 | -69.2 ± 31.06 |
The 4-point pruritus categorical scale was provided in their local language for the participants to report the intensity of their pruritus. Overall itching was scored as 0 for absence of pruritus and 3 for severe pruritus (bothersome itching/scratching that disturbs sleep). Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | 13 | 23 | 31 | 20 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 3 | 9 | 10 | 6 |
| Week 2 | 6 | 19 | 21 | 17 |
| Week 4 | 4 | 19 | 27 | 22 |
| Week 8 | 11 | 22 | 36 | 26 |
| Week 12 | 13 | 26 | 38 | 24 |
| Week 16 | 12 | 30 | 39 | 25 |
| Week 20 | 13 | 27 | 34 | 27 |
| Week 24 | 14 | 25 | 28 | 24 |
SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.
| Percentage change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24 | -42.6 ± 28.25 | -60.8 ± 25.04 | -62.5 ± 25.37 | -55.9 ± 25.85 |
SCORAD ranges from 0 to 103 and has three components: extent (body surface area \[BSA\]), signs, and symptoms of AD. The severity of the 6 signs of AD (erythema/darkening, edema/papulation, oozing/crusting, excoriation, lichenification/prurigo and dryness), was assessed, each on a scale ranging from 0 (none) to 3 (severe).The component of extent corresponded to the extent of BSA affected by atopic dermatitis.The BSA involvement of AD was assessed for each part of the body (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]), and was reported as a percentage of all major body sections combined. Participants were also asked to evaluate their symptoms of pruritus and sleep loss (average for the last 3 days/nights), each evaluated on a Visual analog scale (VAS) from 0 to 10. Higher scores indicate worse outcome.
| units on a scale | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24 | -27.9 ± 19.61 | -40.1 ± 19.19 | -40.6 ± 17.22 | -36.1 ± 16.56 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.
| Percentage change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24 | -50.7 ± 33.52 | -75.4 ± 27.64 | -76.2 ± 23.60 | -74.9 ± 29.39 |
The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night?: On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.
| units on a scale | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24 | -3.9 ± 2.74 | -6.2 ± 2.34 | -5.7 ± 2.51 | -5.8 ± 2.62 |
IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 1 | 1 | 2 | 0 |
| Week 2 | 2 | 1 | 4 | 1 |
| Week 4 | 2 | 1 | 9 | 7 |
| Week 8 | 2 | 3 | 10 | 11 |
| Week 12 | 6 | 6 | 15 | 15 |
| Week 16 | 7 | 9 | 19 | 15 |
| Week 20 | 9 | 11 | 19 | 14 |
| Week 24 | 12 | 14 | 21 | 13 |
EASI is a composite score ranging from 0 to 72. The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 4 | 6 | 12 | 11 |
| Week 2 | 8 | 18 | 18 | 21 |
| Week 4 | 14 | 22 | 29 | 24 |
| Week 8 | 15 | 26 | 31 | 31 |
| Week 12 | 20 | 30 | 36 | 30 |
| Week 16 | 21 | 30 | 34 | 32 |
| Week 20 | 23 | 32 | 38 | 33 |
| Week 24 | 25 | 33 | 38 | 31 |
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 2 | 2 | 3 | 3 |
| Week 2 | 4 | 5 | 6 | 12 |
| Week 4 | 3 | 7 | 12 | 15 |
| Week 8 | 7 | 10 | 21 | 15 |
| Week 12 | 10 | 15 | 25 | 21 |
| Week 16 | 11 | 18 | 28 | 21 |
| Week 20 | 16 | 21 | 25 | 21 |
| Week 24 | 15 | 20 | 26 | 25 |
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification were assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 1 | 1 | 2 | 1 |
| Week 2 | 2 | 0 | 2 | 2 |
| Week 4 | 2 | 1 | 4 | 3 |
| Week 8 | 1 | 3 | 11 | 6 |
| Week 12 | 4 | 7 | 13 | 14 |
| Week 16 | 5 | 10 | 19 | 12 |
| Week 20 | 6 | 13 | 18 | 14 |
| Week 24 | 6 | 13 | 17 | 13 |
IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used to evaluate the global severity of AD. Higher scores indicate worse outcome.
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | 1 | 1 | 2 | 0 |
| Week 2 | 2 | 1 | 4 | 1 |
| Week 4 | 2 | 1 | 9 | 7 |
| Week 8 | 2 | 3 | 10 | 11 |
| Week 12 | 6 | 6 | 15 | 15 |
| Week 16 | 7 | 9 | 19 | 15 |
| Week 20 | 9 | 11 | 19 | 14 |
| Week 24 | 12 | 14 | 21 | 13 |
EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation, excoriation, and lichenification was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. Higher scores indicate worse outcome.
| Percentage of change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | -12.4 ± 24.32 | -22.7 ± 23.54 | -29.3 ± 31.44 | -28.6 ± 25.52 |
| Week 2 | -24.8 ± 29.16 | -34.9 ± 27.70 | -40.1 ± 26.96 | -40.1 ± 32.83 |
| Week 4 | -26.5 ± 33.45 | -40.3 ± 28.36 | -46.7 ± 38.49 | -41.8 ± 41.57 |
| Week 8 | -28.6 ± 36.85 | -42.0 ± 38.15 | -51.7 ± 47.73 | -49.9 ± 37.21 |
| Week 12 | -43.3 ± 35.22 | -58.5 ± 28.16 | -64.1 ± 33.92 | -56.7 ± 37.25 |
| Week 16 | -47.6 ± 32.09 | -59.1 ± 33.09 | -72.2 ± 27.59 | -61.8 ± 41.62 |
| Week 20 | -57.3 ± 31.66 | -67.2 ± 35.18 | -71.6 ± 29.39 | -70.9 ± 27.07 |
| Week 24 | -58.4 ± 31.99 | -72.2 ± 25.96 | -73.4 ± 29.67 | -69.2 ± 31.06 |
Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
| percentage of change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | -9.8 ± 18.47 | -22.6 ± 21.76 | -25.5 ± 30.15 | -19.8 ± 21.16 |
| Week 2 | -12.9 ± 23.97 | -36.9 ± 27.34 | -42.1 ± 23.91 | -37.6 ± 32.29 |
| Week 4 | -16.3 ± 23.77 | -38.7 ± 30.25 | -51.8 ± 26.87 | -45.7 ± 32.64 |
| Week 8 | -23.0 ± 23.88 | -48.2 ± 28.82 | -61.5 ± 24.16 | -58.0 ± 28.63 |
| Week 12 | -28.2 ± 28.83 | -58.0 ± 28.99 | -68.7 ± 25.04 | -56.4 ± 29.81 |
| Week 16 | -36.2 ± 30.25 | -61.4 ± 28.62 | -71.7 ± 22.53 | -63.7 ± 33.07 |
| Week 20 | -38.0 ± 30.11 | -64.6 ± 28.62 | -69.9 ± 26.30 | -69.7 ± 28.47 |
| Week 24 | -42.2 ± 31.66 | -65.8 ± 29.94 | -66.9 ± 38.60 | -68.2 ± 26.88 |
To evaluate the safety of nemolizumab in participants with moderate-to-severe AD
| Participants | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Subjects with treatment-emergent SAEs | 1 | 3 | 2 | 2 |
| Treatment-emergent AEs (TEAE) with fatal outcome | 0 | 1 | 0 | 0 |
| Subjects with TEAE leading to temporary study drug | 0 | 1 | 2 | 1 |
| Subjects with TEAE leading to permanent study drug | 4 | 4 | 2 | 7 |
| Subjects with TEAE leading to study withdrawal | 0 | 3 | 2 | 3 |
| Subjects with at least 1 TEAE | 43 | 47 | 47 | 48 |
| Subjects with severe TEAEs | 6 | 3 | 5 | 2 |
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
| units on a scale | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | -0.9 ± 1.38 | -2.0 ± 1.96 | -2.3 ± 1.89 | -1.7 ± 1.66 |
| Week 2 | -1.2 ± 1.82 | -3.1 ± 2.34 | -3.4 ± 1.96 | -3.3 ± 2.56 |
| Week 4 | -1.4 ± 1.84 | -3.4 ± 2.62 | -4.2 ± 2.21 | -3.8 ± 2.73 |
| Week 8 | -1.9 ± 1.94 | -4.1 ± 2.58 | -5.0 ± 2.14 | -4.7 ± 2.54 |
| Week 12 | -2.3 ± 2.44 | -4.9 ± 2.45 | -5.6 ± 2.29 | -4.7 ± 2.66 |
| Week 16 | -2.9 ± 2.55 | -5.2 ± 2.34 | -5.8 ± 2.25 | -5.1 ± 2.77 |
| Week 20 | -3.1 ± 2.52 | -5.4 ± 2.61 | -5.9 ± 2.22 | -5.4 ± 2.66 |
| Week 24 | -3.5 ± 2.65 | -5.6 ± 2.55 | -5.8 ± 2.54 | -5.5 ± 2.33 |
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
| units on a scale | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | -0.9 ± 1.24 | -2.0 ± 1.94 | -2.3 ± 1.86 | -1.8 ± 1.64 |
| Week 2 | -1.2 ± 1.73 | -3.1 ± 2.32 | -3.3 ± 1.89 | -3.3 ± 2.50 |
| Week 4 | -1.5 ± 1.73 | -3.5 ± 2.47 | -4.1 ± 2.16 | -3.8 ± 2.63 |
| Week 8 | -2.1 ± 1.95 | -4.1 ± 2.42 | -4.9 ± 2.13 | -4.7 ± 2.39 |
| Week 12 | -2.4 ± 2.43 | -4.9 ± 2.48 | -5.5 ± 2.29 | -4.6 ± 2.50 |
| Week 16 | -3.0 ± 2.47 | -5.3 ± 2.18 | -5.7 ± 2.19 | -5.1 ± 2.59 |
| Week 20 | -3.3 ± 2.55 | -5.3 ± 2.47 | -5.8 ± 2.18 | -5.3 ± 2.50 |
| Week 24 | -3.7 ± 2.59 | -5.5 ± 2.53 | -5.6 ± 2.49 | -5.2 ± 2.19 |
Pruritus NRS is a scale to be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For average itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome.
| Percentage of change | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Week 1 | -11.0 ± 16.33 | -24.6 ± 23.39 | -29.4 ± 28.24 | -23.2 ± 22.63 |
| Week 2 | -14.6 ± 23.01 | -39.9 ± 29.89 | -45.2 ± 25.06 | -40.4 ± 33.77 |
| Week 4 | -19.7 ± 22.48 | -43.5 ± 31.66 | -55.8 ± 27.60 | -48.2 ± 33.16 |
| Week 8 | -26.9 ± 25.34 | -52.0 ± 29.50 | -65.1 ± 24.67 | -61.5 ± 28.03 |
| Week 12 | -30.9 ± 31.63 | -61.7 ± 30.02 | -72.2 ± 25.36 | -60.1 ± 29.77 |
| Week 16 | -40.2 ± 31.73 | -66.8 ± 27.02 | -73.9 ± 22.83 | -67.1 ± 31.64 |
| Week 20 | -42.7 ± 32.43 | -67.5 ± 30.03 | -74.5 ± 24.85 | -70.6 ± 29.39 |
| Week 24 | -47.7 ± 32.60 | -68.7 ± 30.60 | -69.9 ± 35.76 | -70.5 ± 26.41 |
Collected over From screening to Follow-up visit (Week 32)/Early termination visit. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/56 (0%) | 1/56 (1.8%) | 43/56 (76.8%) |
| Nemolizumab (10 mg) | 1/55 (1.8%) | 3/55 (5.5%) | 47/55 (85.5%) |
| Nemolizumab (30 mg) | 0/57 (0%) | 2/57 (3.5%) | 47/57 (82.5%) |
| Nemolizumab (90 mg) | 0/57 (0%) | 2/57 (3.5%) | 47/57 (82.5%) |
| Event | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| Staphylococcal sepsisInfections and infestations | 0/56 | 1/55 | 0/57 | 0/57 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/56 | 1/55 | 1/57 | 0/57 |
| Cardio-respiratory arrestCardiac disorders | 0/56 | 1/55 | 0/57 | 0/57 |
| AstheniaGeneral disorders | 0/56 | 1/55 | 0/57 | 0/57 |
| Post-traumatic amnestic disorderPsychiatric disorders | 0/56 | 1/55 | 0/57 | 0/57 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/56 | 1/55 | 0/57 | 0/57 |
| HypertensionVascular disorders | 1/56 | 0/55 | 0/57 | 0/57 |
| CellulitisInfections and infestations | 0/56 | 0/55 | 1/57 | 0/57 |
| Septic shockInfections and infestations | 0/56 | 0/55 | 0/57 | 1/57 |
| Urinary tract infectionInfections and infestations | 0/56 | 0/55 | 0/57 | 1/57 |
| Event | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/56 | 18/55 | 14/57 | 13/57 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 18/56 | 11/55 | 13/57 | 16/57 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/56 | 2/55 | 7/57 | 10/57 |
| HeadacheNervous system disorders | 7/56 | 7/55 | 4/57 | 5/57 |
| Upper respiratory tract infectionInfections and infestations | 1/56 | 4/55 | 6/57 | 4/57 |
| SinusitisInfections and infestations | 0/56 | 4/55 | 3/57 | 1/57 |
| NauseaGastrointestinal disorders | 3/56 | 4/55 | 1/57 | 1/57 |
| Blood creatine phosphokinase increasedInvestigations | 4/56 | 2/55 | 1/57 | 1/57 |
| GastroenteritisInfections and infestations | 1/56 | 0/55 | 3/57 | 4/57 |
| Urinary tract infectionInfections and infestations | 3/56 | 3/55 | 1/57 | 1/57 |
Intent-to-treat (ITT) population included all randomized participants. The ITT population was analyzed according to the treatment groups or stratum assigned at randomization.
| Age, Categorical(Participants) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 54 | 53 | 51 | 51 | 209 |
| >=65 years | 3 | 2 | 6 | 6 | 17 |
| Age, Continuous(years) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| Mean | 40.9 ± 15.01 | 35.3 ± 14.83 | 40.2 ± 16.64 | 40.9 ± 14.95 | 39.3 ± 15.45 |
| Sex: Female, Male(Participants) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| Female | 26 | 26 | 28 | 31 | 111 |
| Male | 31 | 29 | 29 | 26 | 115 |
| Race (NIH/OMB)(Participants) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 4 | 11 | 6 | 4 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 3 | 10 | 8 | 29 |
| White | 45 | 38 | 40 | 44 | 167 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 1 | 1 | 4 |
| Height(centimetre) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| Mean | 170.0 ± 10.28 | 169.7 ± 8.98 | 171.5 ± 8.55 | 170.6 ± 9.94 | 170.5 ± 9.43 |
| Weight(kilogram) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| Mean | 80.58 ± 18.835 | 73.72 ± 14.629 | 76.90 ± 18.613 | 80.49 ± 22.770 | 77.96 ± 19.052 |
| Body mass index(kilogram per square metre) | Placebo | Nemolizumab (10 mg) | Nemolizumab (30 mg) | Nemolizumab (90 mg) | Total |
|---|---|---|---|---|---|
| Mean | 27.79 ± 5.638 | 25.54 ± 4.429 | 26.18 ± 6.370 | 27.51 ± 6.694 | 26.77 ± 5.894 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Jul 2018, 13 months.
Results were first posted in Oct 2019, 1 year 3 months after primary completion.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab